Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 25, Issue 1, 2007, Pages 76-84

  Coen, John J ^a   Zietman, Anthony L ^a   Kaufman, Donald S ^a   Shipley, William U ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bladder cancer; Bladder preservation; Combined modality therapy; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ACCURACY; ADVANCED CANCER; BLADDER CANCER; BLADDER FUNCTION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER INVASION; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CYSTECTOMY; CYSTOSCOPY; HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; REVIEW; TECHNIQUE; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT INDICATION; TUMOR BLEEDING; UNITED STATES; UNSPECIFIED SIDE EFFECT;

BENCHMARKING; CYSTECTOMY; HUMANS; MUSCLE, SMOOTH; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 33845896538     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.05.012     Document Type: Review

References (36)

1. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349 (2003) 859-866
2. Shih H.A., Harisinghani M., Zietman A.L., et al. Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys 63 (2005) 1262-1269
3. Cowan R.A., McBain C.A., Ryder W.D., et al. Radiotherapy for muscle-invasive carcinoma of the bladder: Results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 197-207
4. Roof K., Mazal A., Sarkar S., et al. A three-dimensional CT based analysis of inter-fraction bladder motion during radiotherapeutic treatment of bladder cancer (2004) Paper presented at: American Society for Therapeutic Radiology and Oncology, Atlanta, GA
5. Brown Jr. A.L., Zietman A.L., Shipley W.U., et al. An organ-preserving approach to muscle-invading transitional cell cancer of the bladder. Hematol Oncol Clin North Am 15 (2004) 345-358
6. Housset M., Maulard C., Chretien Y., et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study. J Clin Oncol 11 (1993) 2150-2157
7. Rodel C., Grabenbauer G.G., Kuhn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 20 (2002) 3061-3071
8. Miller L.S. Bladder cancer: Superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 39 (1977) 973-980
9. Bloom H.J., Hendry W.F., Wallace D.M., et al. Treatment of T3 bladder cancer: Controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 54 (1982) 136-151
10. Sell A., Jakobsen A., Nerstrom B., et al. Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl 138 (1991) 193-201
11. Hagan M.P., Winter K.A., Kaufman D.S., et al. RTOG 9706: Initial report of a phase I/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with Cisplatin followed by adjuvant MCV chemotherapy. Int J Radiat Oncol Biol Phys 51 (2001) 14
12. Tester W., Porter A., Asbell S., et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25 (1993) 783-790
13. Shipley W.U., Winter K.A., Kaufman D.S., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16 (1998) 3576-3583
14. Chakravarti A., Winter K., Wu C.L., et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 62 (2005) 309-317
15. Shipley W.U., Kaufman D.S., Zehr E., et al. Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer. Urology 60 (2002) 62-67
16. Coen J.J., Heney N.M., Althausen A.F., et al. An Update of Selective Bladder Preservation Using Combined Modality Treatment in Invasive Bladder Cancer: Long Term Outcomes Reveals a Low Risk of Invasive Recurrence and High Probability of Bladder Preservation: American Urologic Association. J Urol (2004) 171 San Francisco, CA [Abstract 308].
17. Zietman A.L., Grocela J., Zehr E., et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: Management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 58 (2001) 380-385
18. Zietman A.L., Sacco D., Skowronski U., et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-term survivors. J Urol 170 (2003) 1772-1776
19. Caffo O., Fellin G., Graffer U., et al. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire. Cancer 78 (1996) 1089-1097
20. Henningsohn L., Steven K., Kallestrup E.B., et al. Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol 168 (2002) 168-174
21. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
22. Dalbagni G., Genega E., Hashibe M., et al. Cystectomy for bladder cancer: A contemporary series. J Urol 165 (2001) 1111-1116
23. Sweeney P., Kursh E.D., and Resnick M.I. Partial cystectomy. Urol Clin North Am 19 (1992) 701-711
24. Cole C.J., Pollack A., Zagars G.K., et al. Local control of muscle-invasive bladder cancer: Preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 32 (1995) 331-340
25. Srinivasan V., Brown C.H., and Turner A.G. A comparison of two radiotherapy regimens for the treatment of symptoms from advanced bladder cancer. Clin Oncol (R Coll Radiol) 6 (1994) 11-13
26. Salminen E. Unconventional fractionation for palliative radiotherapy of urinary bladder cancer. A retrospective review of 94 patients. Acta Oncol 31 (1992) 449-454
27. Aass N., and Fossa S.D. Aims and results of palliative radiotherapy in urological cancer. Curr Opin Oncol 6 (1994) 308-312
28. Duchesne G.M., Bolger J.J., Griffiths G.O., et al. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: Results of medical research council trial BA09. Int J Radiat Oncol Biol Phys 47 (2000) 379-388
29. Ben-Josef E., Shamsa F., Williams A.O., et al. Radiotherapeutic management of osseous metastases: A survey of current patterns of care. Int J Radiat Oncol Biol Phys 40 (1998) 915-921
30. Tong D., Gillick L., and Hendrickson F.R. The palliation of symptomatic osseous metastases: Final results of the Study by the Radiation Therapy Oncology Group. Cancer 50 (1982) 893-899
31. Price P., Hoskin P.J., Easton D., et al. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 6 (1986) 247-255
32. Hoskin P.J., Price P., Easton D., et al. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 23 (1992) 74-78
33. Okawa T., Kita M., Goto M., et al. Randomized prospective clinical study of small, large and twice-a-day fraction radiotherapy for painful bone metastases. Radiother Oncol 13 (1988) 99-104
34. Madsen E.L. Painful bone metastasis: Efficacy of radiotherapy assessed by the patients: A randomized trial comparing 4 Gy X 6 versus 10 Gy X 2. Int J Radiat Oncol Biol Phys 9 (1983) 1775-1779
35. Hartsell W.F., Scott C.B., Bruner D.W., et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97 (2005) 798-804
36. Wu J.S., Wong R., Johnston M., et al. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55 (2003) 594-605